Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development-Reference-Cited by-同舟云学术

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Published:2014-02-05 Issue:4 Volume:57 Page:1454-1472
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Sun Daqing¹²³,Li Zhihong¹²³,Rew Yosup¹²³,Gribble Michael¹²³,Bartberger Michael D.¹²³,Beck Hilary P.¹²³,Canon Jude¹²³,Chen Ada¹²³,Chen Xiaoqi¹²³,Chow David¹²³,Deignan Jeffrey¹²³,Duquette Jason¹²³,Eksterowicz John¹²³,Fisher Benjamin¹²³,Fox Brian M.¹²³,Fu Jiasheng¹²³,Gonzalez Ana Z.¹²³,Gonzalez-Lopez De Turiso Felix¹²³,Houze Jonathan B.¹²³,Huang Xin¹²³,Jiang Min¹²³,Jin Lixia¹²³,Kayser Frank¹²³,Liu Jiwen (Jim)¹²³,Lo Mei-Chu¹²³,Long Alexander M.¹²³,Lucas Brian¹²³,McGee Lawrence R.¹²³,McIntosh Joel¹²³,Mihalic Jeff¹²³,Oliner Jonathan D.¹²³,Osgood Tao¹²³,Peterson Matthew L.¹²³,Roveto Philip¹²³,Saiki Anne Y.¹²³,Shaffer Paul¹²³,Toteva Maria¹²³,Wang Yingcai¹²³,Wang Yu Chung¹²³,Wortman Sarah¹²³,Yakowec Peter¹²³,Yan Xuelei¹²³,Ye Qiuping¹²³,Yu Dongyin¹²³,Yu Ming¹²³,Zhao Xiaoning¹²³,Zhou Jing¹²³,Zhu Jiang¹²³,Olson Steven H.¹²³,Medina Julio C.¹²³

Affiliation:

1. Departments of Therapeutic Discovery, ‡Pharmaceutics, and §Pharmacokinetics and Drug Metabolism, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California, 94080, United States

2. Departments of Therapeutic Discovery, and ⊥Oncology Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States

3. Departments of Therapeutic Discovery, and ∇Pharmaceutics, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm401753e

Reference26 articles.

1. The genetics of the p53 pathway, apoptosis and cancer therapy

2. Inhibiting the p53–MDM2 interaction: an important target for cancer therapy

3. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein